Stock 7325 IRRC CORPORATION
Add to a list
To use this feature you must be a member
Log inSign up

All News IRRC Corporation

Equities

7325

JP3105230001

Delayed Japan Exchange
Other stock markets
 09:30:47 2024-05-06 pm EDT 		5-day change 1st Jan Change
720 JPY +0.42% Intraday chart for IRRC Corporation -0.83% +11.46%
Feb. 19 Tranche Update on IRRC Corporation's Equity Buyback Plan announced on August 18, 2023. CI
Feb. 16 IRRC Corporation's Equity Buyback announced on August 18, 2023, has closed with 200,000 shares, representing 2.39% for ¥140.90 million. CI

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Tranche Update on IRRC Corporation's Equity Buyback Plan announced on August 18, 2023.
CI
IRRC Corporation's Equity Buyback announced on August 18, 2023, has closed with 200,000 shares, representing 2.39% for ¥140.90 million.
CI
Tranche Update on IRRC Corporation's Equity Buyback Plan announced on August 18, 2023.
CI
Henlius Biotech, Inc. - Results from Four Phase 1/2 Clinical Trials of Henlius Innovative Products Released at 2023 ESMO Asia
AQ
Tranche Update on IRRC Corporation's Equity Buyback Plan announced on August 18, 2023.
CI
IRRC Corporation completed the acquisition of 80.9% stake in Life Assist Co., Ltd. from Orix Life Insurance Corporation.
CI
IRRC Corporation announces an Equity Buyback for 200,000 shares, for ¥160 million.
CI
IRRC Corporation authorizes a Buyback Plan.
CI
Tranche Update on IRRC Corporation's Equity Buyback Plan announced on February 14, 2023.
CI
IRRC Corporation's Equity Buyback announced on February 14, 2023, has closed with 300,300 shares, representing 3.48% for ¥228.63 million.
CI
IRRC Corporation signed a basic agreement to acquire a 80.9% stake in Life Assist Co., Ltd. from Orix Life Insurance Corporation for approximately ¥400 million.
CI
Tranche Update on IRRC Corporation's Equity Buyback Plan announced on February 14, 2023.
CI
IRRC Corporation Reports Earnings Results for the Nine Months Ended March 31, 2023
CI
Tranche Update on IRRC Corporation's Equity Buyback Plan announced on February 14, 2023.
CI
CStone Announces Publication of GEMSTONE-201 Study Results for Sugemalimab Monotherapy in the Treatment of Relapsed, Refractory Extranodal NK/T-Cell Lymphoma in Journal of Clinical Oncology
AQ
IRRC Corporation announces an Equity Buyback for 500,000 shares, representing 5.74% for ¥400 million.
CI
IRRC Corporation authorizes a Buyback Plan.
CI
Kyowa Kirin and MEI Pharma Announce Topline Data from the Phase 2 MIRAGE Study Evaluating Zandelisib in Patients with Indolent B-cell non-Hodgkin's Lymphoma in Japan
AQ
CStone presents clinical results of sugemalimab in patients with relapsed or refractory extranodal natural killer/T-cell lymphoma via an oral abstract session at ASCO 2022
AQ
IRRC : Pennsylvania Takes Next Step Toward Cap-and-Trade Amid Resistance
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. 7325 Stock
  4. News IRRC Corporation
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW